K
Keren Asraf
Researcher at Sheba Medical Center
Publications - 33
Citations - 755
Keren Asraf is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 6 publications receiving 104 citations. Previous affiliations of Keren Asraf include United States Public Health Service.
Papers
More filters
letters-and-commentsDOI
Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
Gili Regev-Yochay,Tal Gonen,Mayan Gilboa,Michal Mandelboim,Victoria Indenbaum,Sharon Amit,Lilac Meltzer,Keren Asraf,Carmit Cohen,Ronen Fluss,Asaf Biber,Ital Nemet,L. Kliker,Gili Joseph,Ram Doolman,Ella Mendelson,Laurence S. Freedman,Dror Harats,Yitshak Kreiss,Yaniv Lustig +19 more
Journal ArticleDOI
Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses.
Yaniv Lustig,Shlomit Keler,Shlomit Keler,Rachel Kolodny,Nir Ben-Tal,Danit Atias-Varon,Ekaterina Shlush,Motti Gerlic,Ariel Munitz,Ram Doolman,Ram Doolman,Keren Asraf,Liran I. Shlush,Asaf Vivante,Asaf Vivante +14 more
TL;DR: Findings support possible cross-reactivity between dengue virus and SARS-CoV-2, which can lead to false-positive d Dengue serology among COVID-19 patients and vice versa and have serious consequences for both patient care and public health.
Journal ArticleDOI
Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
S. Bookstein Peretz,S. Bookstein Peretz,N. Regev,L. Novick,M. Nachshol,E. Goffer,A. Ben‐David,A. Ben‐David,Keren Asraf,Ram Doolman,E. Gal Levin,E. Gal Levin,G. Regev Yochay,G. Regev Yochay,Yoav Yinon,Yoav Yinon +15 more
TL;DR: In this article, a case-control study of pregnant women who were vaccinated with a two-dose regimen of BNT162b2 vaccine during gestation between January and February 2021 (study group) and age matched non-pregnant women who received the vaccine during the same time period (control group).
Journal ArticleDOI
Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy.
Omer Nir,Omer Nir,Anat Schwartz,Anat Schwartz,Shlomi Toussia-Cohen,Shlomi Toussia-Cohen,Leah Leibovitch,Leah Leibovitch,Tzipi Strauss,Tzipi Strauss,Keren Asraf,Ram Doolman,Sivan Sharabi,Carmit Cohen,Carmit Cohen,Yaniv Lustig,Yaniv Lustig,Gili Regev-Yochay,Gili Regev-Yochay,Yoav Yinon,Yoav Yinon +20 more
TL;DR: In this paper, a prospective cohort study was conducted in a single tertiary medical center in Israel between February and March 2021, where parturient women vaccinated with the BNT162b2 messenger RNA vaccine during pregnancy were included and compared with COVID-19-recovered women.
Journal ArticleDOI
Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
Mayan Gilboa,Gili Regev-Yochay,Michal Mandelboim,Victoria Indenbaum,Keren Asraf,Ronen Fluss,Sharon Amit,Ella Mendelson,Ram Doolman,Arnon Afek,Laurence S. Freedman,Yitshak Kreiss,Yaniv Lustig +12 more
TL;DR: This cohort study investigates antibody waning after second and third doses of the BNT162b2 (BioNTech/Pfizer) COVID-19 vaccine.